Bio-Techne Corp (NASDAQ:TECH) announced its earnings results on Tuesday. The biotechnology company reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.99 by $0.10, Bloomberg Earnings reports. The firm had revenue of $156.60 million during the quarter, compared to analysts’ expectations of $150.25 million. Bio-Techne Corp had a return on equity of 13.80% and a net margin of 12.86%. The company’s revenue was up 16.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.92 earnings per share.

Shares of Bio-Techne Corp (NASDAQ TECH) traded down 2.03% on Tuesday, hitting $113.87. The stock had a trading volume of 245,906 shares. The stock’s 50-day moving average price is $115.98 and its 200 day moving average price is $108.12. The company has a market cap of $4.25 billion, a PE ratio of 61.25 and a beta of 0.79. Bio-Techne Corp has a 52 week low of $95.68 and a 52 week high of $121.94.

TECH has been the subject of a number of recent analyst reports. Deutsche Bank AG reaffirmed a “buy” rating and set a $122.00 target price (up previously from $115.00) on shares of Bio-Techne Corp in a research report on Wednesday, May 3rd. BidaskClub raised Bio-Techne Corp from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Zacks Investment Research raised Bio-Techne Corp from a “hold” rating to a “buy” rating and set a $131.00 target price for the company in a research report on Thursday, July 6th. TheStreet raised Bio-Techne Corp from a “c+” rating to a “b” rating in a research report on Tuesday, May 2nd. Finally, Wells Fargo & Company initiated coverage on Bio-Techne Corp in a research report on Thursday, July 13th. They set a “market perform” rating for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $123.20.

In other news, Director Karen A. Holbrook sold 5,000 shares of Bio-Techne Corp stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $111.15, for a total transaction of $555,750.00. Following the completion of the transaction, the director now directly owns 6,973 shares in the company, valued at approximately $775,048.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 10,300 shares of company stock valued at $1,146,707 over the last quarter. 2.70% of the stock is currently owned by corporate insiders.

WARNING: “Bio-Techne Corp (TECH) Issues Earnings Results” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at

Bio-Techne Corp Company Profile

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Earnings History for Bio-Techne Corp (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with's FREE daily email newsletter.